Stock Update (NYSE:CVS): CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies

[PR Newswire] – WOONSOCKET, R.I., Sept. 17, 2014 /PRNewswire/ — An analysis done by the CVS Health Research Institute provides insights regarding patients taking Sovaldi® (sofosbuvir), a new and expensive treatment for Hepatitis . . . → Read More: Stock Update (NYSE:CVS): CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies Similar Articles: Stock Update: CVS Caremark Corporation (NYSE:CVS) – CVS Caremark Announces New Clinical Affiliation with MedStar Health Stock Update (NYSE:ABBV): AbbVie files New Drug Submission to Health Canada for its investigational, all-oral, interferon-free therapy for the treatment of hepatitis C Market Update (NYSE:CVS): CVS Caremark Announces New Clinical Affiliations with Four Major Regional Health Systems